IRulya Therapeutics presents LAM-001 Phase 2a data in pulmonary hypertension
IRLA•IRulya Therapeutics reported that four evaluable patients in a Phase 2a trial of inhaled rapamycin LAM-001 for PH-ILD improved their six-minute walk distance by 67.4 meters at 24 weeks. The company raised $115 million upfront in May 2026.
1. Phase 2a results
In Phase 2a testing of LAM-001 for pulmonary hypertension associated with interstitial lung disease (PH-ILD), four evaluable patients showed a 67.4-meter improvement in six-minute walk distance at 24 weeks.
2. Trials and financing
IRulya expects Phase 2 data for LAM-001 in bronchiolitis obliterans syndrome in the first quarter of 2027. Its ongoing PH-ILD Phase 2b trial targets 75 patients, with data anticipated in the first quarter of 2028. A Phase 2 trial in sarcoidosis-associated pulmonary hypertension is expected to start in the fourth quarter of 2026, with data anticipated in the fourth quarter of 2028. The company raised $115 million upfront in an oversubscribed financing in May 2026.
